Yasmin Articles
Mixed views on drospirenone OCs
9 December 2011
Pfizer gains six months patent life for Lipitor on pediatric data; Bayer Yasmin patent scotched
11 July 2011
Two new studies find Bayer's contraceptives Yaz and Yasmin have an increased risk of blood clots
26 April 2011
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Teva's 1st-qtr profit more than triples
6 May 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Teva gets FDA appro for generic Yaz
3 April 2009
Bayer must retract television adverts for Yaz to settle law suit
16 February 2009
Bayer updates press on current pipeline
12 January 2009
Barr's 2nd-qtr 2008 profit rises 27%
18 August 2008
Bayer's 2nd-qtr 2008 net profit falls 13%
11 August 2008
Bayer enters generic Yasmin deal with Barr
30 June 2008
Stock Commentary - New York week to May 26, 2008
2 June 2008
Bayer Schering to market Yaz in EU
12 May 2008
Stock Commentary - Europe - week to March 10, 2008
17 March 2008
Stock Commentary - New York week to March 10, 2008
17 March 2008
US court rules patent for Yasmin is invalid
10 March 2008
Bayer's 4th-qtr 2007 profit plummets 76% to 67M euros, well below analyst expectations
10 March 2008
Watson files ANDA for generic of Bayer-Schering's Yaz
19 November 2007
Yaz approved in the Netherlands
16 July 2007
Bayer and Intendis to promote Yaz for acne
14 May 2007
Yaz cleared for acne by the FDA
5 February 2007
Schering AG buy boosts Bayer but charges take toll on profit; 3rd-qtr beats forecasts
4 December 2006
FDA OKs new indiction for Schering AG's YAZ
9 October 2006
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
16% 1st-qtr 2006 sales rise for Schering AG
24 April 2006
Schering AG's Yaz gets FDA go ahead
27 March 2006
Schering AG sees 2005 net leap 23%
27 February 2006
US FDA gives tentative OK for Schering's Yaz in PMDD
30 January 2006
FDA extends review of Schering's Yaz NDA
19 December 2005
Schering AG gets approval in the Netherlands for Yasminelle
22 August 2005
Schering AG 1st-half profits leap 23%
1 August 2005
Schering AG opens Asia-Pacific HQ in Singapore
20 June 2005
Barr confirms filing in USA for Yasmin
4 April 2005
Schering AG's Yasmin under pressure in USA
28 March 2005
FDA approvable letter for Schering AG's Yaz
22 November 2004
Schering AG's three-qtr EPS rises 12%
25 October 2004
Additional patent for Schering AG's Yasmin
20 September 2004
Schering AG raises 2004 forecast on 2nd-qtr
2 August 2004
Schering-AG's low-dose Yasmin delayed
26 July 2004
Letter from the Editor
21 June 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Schering AG reports 6% "organic" sales growth for 2003
9 February 2004
Schering AG files NDA for low-dose Yasmin
22 December 2003
Schering AG sees strong profit growth
3 November 2003
Indian pharmaceutical news in brief
13 October 2003
Profits and sales down at Schering AG
11 August 2003
Galen Merger talks terminated
28 July 2003
Schering AG beats forecasts in 2002
10 March 2003
Update: Sales up 11% at Schering AG
10 March 2003
Schering AG's 2002 sales disappoint
10 February 2003
D&TB dismisses weight-neutral claims for Yasmin
19 August 2002
Schering AG US sales up 22% in Q2
5 August 2002
Schering AG's 1st-qtr sales rise 7%
6 May 2002
Yasmin under fire in the Netherlands?
29 April 2002
Schering AG CEO optimistic about firm's future prospects
22 April 2002
Schering's Yasmin launched in UK
22 April 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Schering AG's Yasmin for severe PMS?
23 August 2001
Schering AG raises earnings expectations
27 July 2001
Schering AG launches Yasmin OC in USA
26 June 2001
Schering AG acquires 24.5% of Molypharma
1 June 2001
Schering AG's Yasmin registered in USA
21 May 2001
Schering AG to focus on special markets
20 April 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
